Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA-E in NASH
NCT01154985Phase 2Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Jun 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Epadel in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoints: Histological Response Defined by Change From Baseline in Standardized Scoring of Liver Biopsies at 12 months and Alanine Transaminase Levels at 6 months. Started Jun 2010; status: completed.
02
Drugs
Epadel
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT01154985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154985.